OpenEvidence
AI copilot for doctors that helps them make high stakes decisions at the point of care.
About OpenEvidence
Launched during the Mayo Clinic Platform Accelerate program, featured by the New England Journal of Medicine AI, and powering Elsevier’s ClinicalKey AI (Lancet; Cell; Gray's Anatomy; 2000+ journals), OpenEvidence is the world’s leading AI medical information platform.
OpenEvidence is the world’s leading medical information platform for health care professionals, providing accurate and efficient answers at the point of care. Every answer on OpenEvidence is always sourced, cited, and grounded in the peer-reviewed medical literature.
Now featuring New England Journal of Medicine (NEJM) published content, NEJM multimedia content, and NEJM invited review articles authored by the world’s leading clinical experts.
• 160 medical specialties
• 1,000+ diseases and therapeutic areas
• 1m+ medical topics
Trusted by medical professionals at 10,000+ care centers across the United States.
Investors include Sequoia Capital, Breyer Capital, Mayo Clinic, Elsevier, and others
Company details
Funding
Total raised
$700M
Last stage
Series D
Investors
Founders
Daniel Nadler
Harvard Ph.D., serial entrepreneur, and former founder of Kensho, a financial analytics firm acquired by S&P Global in 2018.
Zack Ziegler
Machine learning researcher from Harvard who co-founded OpenEvidence with Daniel Nadler to address challenges in medical literature for physicians.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.